Ending Leukemia: Major Development Announced By This Medical Company

Groundbreaking Results: Jasper Therapeutics' Phase 1 Study of Briquilimab Demonstrates Promising Results for AML and MDS Patients.

In a remarkable development for the medical community, Jasper Therapeutics, Inc., a leading biotechnology company, has announced positive final results from its Phase 1 study of Briquilimab in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) undergoing Hematopoietic Cell Transplant. The announcement was made during an oral p…